A carregar...
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
BACKGROUND: Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were s...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2006
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1712353/ https://ncbi.nlm.nih.gov/pubmed/17150109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-278 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|